Investing Profile

Todd Foley

VCInvestor
Managing Director at MPM BioImpact
mpmcapital.com/team/Boston, Massachusetts
Photo of Todd Foley, Managing Director at MPM BioImpact

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Massachusetts Institute of Technology Network
628 CONNECTIONS
Genentech Network
75 CONNECTIONS
MPM BioImpact Network
34 CONNECTIONS
Arthur D. Little Network
25 CONNECTIONS
cb
MPM BioImpact Managing Director
$1M - $150.0M
$25.0M
17
CompanyStageDateRound SizeTotal Raised
Crossbow Therapeutics
Series BMar 2026$77M
Series AJul 2023$80M
$160M
Co-investors: Sakae Asanuma (Astellas Pharma US)
āshibio
Series AJun 2024$40M
$40M
Firefly Bio
Series AFeb 2024$94M
$94M
Co-investors: Jerel Davis (Versant Ventures)
Aktis Oncology
Series AAug 2022$84M
Series AMar 2021$72M
$330M
Co-investors: Jason Ruth (M Ventures (Merck)), Andrew Levin (RA Capital Management)
Iconic Therapeutics
Series UnknownJun 2018$4M
Series CAug 2016$10M
Series CJan 2016$40M
Series BApr 2014$20M
$74M
Co-investors: William Greene (MPM BioImpact)
Semma Therapeutics
Series AMar 2015$44M
$44M
Co-investors: Stephen Oesterle
Clinical Ink
Series UnknownMar 2015$20M
$20M
Chiasma
Series EFeb 2015$70M
Series DJul 2012$39M
Series CNov 2006$44M
$160M
Co-investors: Bard Geesaman (Barron Park Association), Scott Minick (ARCH Venture Partners), Ansbert Gadicke (MPM Capital), Vincent Miles (Abingworth)
Analyst Arthur D. LittlePresent
Business Development Intern GenentechPresent
Managing Director MPM BioImpactPresent
BIS BS Chemistry
Massachusetts Institute of Technology BS Chemistry
Sign in with Google →
Sign in with Google →